73 related articles for article (PubMed ID: 19845435)
1. Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects.
Zeng Y; He FY; He YJ; Dai LL; Fan L; Zhou HH
Xenobiotica; 2009 Nov; 39(11):844-9. PubMed ID: 19845435
[TBL] [Abstract][Full Text] [Related]
2. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
3. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
[TBL] [Abstract][Full Text] [Related]
4. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers.
Fan L; Mao XQ; Tao GY; Wang G; Jiang F; Chen Y; Li Q; Zhang W; Lei HP; Hu DL; Huang YF; Wang D; Zhou HH
Xenobiotica; 2009 Mar; 39(3):249-54. PubMed ID: 19280523
[TBL] [Abstract][Full Text] [Related]
5. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
6. Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism.
He X; Mo L; Li ZY; Tan ZR; Chen Y; Ouyang DS
Xenobiotica; 2012 Dec; 42(12):1248-54. PubMed ID: 22725663
[TBL] [Abstract][Full Text] [Related]
7. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
8. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
9. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
Gramatté T; Oertel R; Terhaag B; Kirch W
Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
Yan M; Fang PF; Li HD; Xu P; Liu YP; Wang F; Cai HL; Tan QY
Eur J Clin Pharmacol; 2013 Mar; 69(3):515-21. PubMed ID: 22983284
[TBL] [Abstract][Full Text] [Related]
11. Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants.
Xiao CQ; Chen R; Lin J; Wang G; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2012 Feb; 42(2):173-8. PubMed ID: 21943317
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Oertel R; Kirch W
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):161-7. PubMed ID: 10783825
[TBL] [Abstract][Full Text] [Related]
14. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.
Trausch B; Oertel R; Richter K; Gramatté T
Biopharm Drug Dispos; 1995 Jul; 16(5):403-14. PubMed ID: 8527689
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
[TBL] [Abstract][Full Text] [Related]
16. High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.
Nguyen MA; Staubach P; Tamai I; Langguth P
Eur J Pharm Sci; 2015 Feb; 68():36-42. PubMed ID: 25486333
[TBL] [Abstract][Full Text] [Related]
17. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol.
Lilja JJ; Backman JT; Laitila J; Luurila H; Neuvonen PJ
Clin Pharmacol Ther; 2003 Mar; 73(3):192-8. PubMed ID: 12621384
[TBL] [Abstract][Full Text] [Related]
18. Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects.
Zeng Y; He YJ; He FY; Fan L; Zhou HH
Acta Pharmacol Sin; 2009 Apr; 30(4):478-84. PubMed ID: 19343062
[TBL] [Abstract][Full Text] [Related]
19. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.
Juan H; Terhaag B; Cong Z; Bi-Kui Z; Rong-Hua Z; Feng W; Fen-Li S; Juan S; Jing T; Wen-Xing P
Eur J Clin Pharmacol; 2007 Jul; 63(7):663-8. PubMed ID: 17468862
[TBL] [Abstract][Full Text] [Related]
20. Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study.
Sourgens H; Schmidt J; Derendorf H
Int J Clin Pharmacol Ther; 2003 Jan; 41(1):22-9. PubMed ID: 12564742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
